News
Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...
Stylus will use the Eli Lilly and J&J-backed funds to advance its in vivo genetic medicines platform and develop its pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback